The nation of Zimbabwe has declined a substantial American health deal valued at $367m (£272m) spanning five years over the United States' request for sensitive information.
The decision came to light following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative has since stated that the US was seeking health data for research and commercial purposes but was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued negotiations to reach a agreement agreeable to all parties so the country's vital HIV programme can be sustained.
Broader Implications
This rejection comes after a similar situation in Kenya, where a court suspended a similar deal with the US following legal challenges were filed about the security of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered aid for the US government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to boost transparency and responsibility.
Based on reports, 16 African countries have to date signed similar agreements, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, without any corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our population should a future disease outbreak emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the global health body and its pursuit of bilateral deals were upending structures previously established through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how subsequent co-operation could be structured in a way that honours the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body expressed it recognised the official position, but suggested that negotiations must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"In cases where technical issues arise, such as those involving information security or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," the group commented.
The situation highlights the ongoing tensions between receiving much-needed international aid and safeguarding national sovereignty in an increasingly data-driven world.